Amgen's Aimovig Riding High With Strong Prescriber, Payer Acceptance
New commercial head Murdo Gordon described Aimovig as one of the best launches he's ever seen and said growth should continue – though moderate – based on prescriber experience and rapid transitions from free drug to reimbursed prescriptions.
You may also be interested in...
With Neulasta and Epogen facing competition and potential Sensipar generics launching this year, the company said revenues will fall from $23.7bn in 2018 to $21.8bn-$22.9bn in 2019. Amgen expects new launches and volume-driven sales growth – not price hikes – to boost revenue in the future.
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.
The company's $2.1bn acquisition of Endocyte and expansion into radiopharmaceuticals dominated some of the call, but with the launches of drugs like Cosentyx, Kymriah, Kisqali and Aimovig underway, there was a lot for Novartis' management team to address.